Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Tesaro
Biotech
Xencor sells ex-lead drug to Tesaro founder in backloaded deal
Almost three years after deciding to partner in the wake of a failed trial, Xencor has offloaded the drug to Zenas in a deal worth up to $480 million.
Nick Paul Taylor
Nov 22, 2021 8:45am
AbbVie, Roche top data transparency list in new Yale report
Jul 21, 2021 10:15am
GSK posts middling data from PD-1 Tesaro buyout drug
Apr 24, 2020 8:35am
GlaxoSmithKline talks up new R&D focus, keeps mum on M&A
Feb 6, 2020 7:34am
JPM Tuesday: Pfizer's pipeline, 2020's bolt-on deals
Jan 15, 2020 7:50am
ESMO: AbbVie's PARP inhibitor veliparib finally gets a win
Sep 29, 2019 4:16am